In the present study, our focus is solely on providing the first in vitro and in vivo evidence supporting the utility of SPINK1 as a plasma biomarker for tumor hypoxia, and we will report the results of analysis with cancer patients in our next paper. This evidence concerns the gene SPINK1 and cancer.